Melanoma vaccines: trials and tribulations

References

• Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000;343(1):37–49.
   PubMed Web of Science ®Google Scholar
• Delves PJ, Roitt IM. The immune system. Second of two parts. N Engl J Med. 2000;343(2):108–117.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med. 2008(25);358: 2704–2715.
   Google Scholar
• Schreiber RD, Old IJ, Smyth MJ. Cancer immunoediting: integrating immunity’s role in cancer suppression and promotion. Science. 2011;331(6024):1565–1570.
   PubMed Web of Science ®Google Scholar
• Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm. 2011;26(1):1–64.
   PubMed Web of Science ®Google Scholar
• Bulkley G, Cohen MH, Banks PM, Char DH, Ketcham AS. Longterm spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile. Cancer. 1975;36(2):485–494.
   Google Scholar
• Kalialis LV, Drzewiecki KT, Klwer H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009;19(5):275–282.
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77(7):1303–1310.
   PubMed Web of Science ®Google Scholar
• Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest. 1996;74(1):43–47.
   PubMed Web of Science ®Google Scholar
• Holmes EC, Eilber FR, Morton DL. Immunotherapy of malignancy in humans. Current status. JAMA. 1975;232(10):1052–1055.
   Web of Science ®Google Scholar
• Stewart JH 4th, Levine EA. Role of bacillus Calmette-Guerin in the treatment of advanced melanoma. Expert Rev Anticancer Ther. 2011;11(11):1671–1676.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7–17.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol. 2012;30(31):3810–3818.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105–2116.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Topolian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (Anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti- PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354(7):709–718.
   PubMed Web of Science ®Google Scholar
• Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19(15):3477–3482.
   PubMed Web of Science ®Google Scholar
• Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother. 2009;58(5):823–830.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol. 2002;20(17):3703–3718.
   PubMed Web of Science ®Google Scholar
• Dillman RO. The clinical experience with interleukin-2 in cancer therapy. Cancer Biother. 1994;9(3):183–209.
   PubMedGoogle Scholar
• Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park). 2002;16(11 Suppl 13):11–20.
   Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889–897.
   PubMed Web of Science ®Google Scholar
• West WH, Tauer KW, Yannelli JR, et al. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl JMed. 1987;316(15):898–905.
   PubMed Web of Science ®Google Scholar
• Dutcher JP Gaynor ER, Fisher RI, et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol. 1991;9(4):641–648.
   Web of Science ®Google Scholar
• Dillman RO, Oldham RK, Tauer KW, et al. Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol. 1991;9(7):1233–1340.
   Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine- activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85(8):622–632.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor- infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–1680.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Oldham RK, Barth NM, et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trial. Cancer. 1991;68(1):1–8.
   Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346–2357.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immuotherapy. Clin Cancer Res. 2011;17(13):4550–4557.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, et al. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. JClin Oncol. 2013;31(17):152–159.
   Web of Science ®Google Scholar
• Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539–550.
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines. 2002;1(1):111–118.
   PubMedGoogle Scholar
• Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;(105):487–511.
   Google Scholar
• Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;20(25)(Pt 1)290:1413–1420.
   Google Scholar
• Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290(26)(Pt 2):1458–1469.
   Google Scholar
• Vosika GJ. Clinical immunotherapy trials of bacterial components derived from Mycobacteria and Nocardia. J Biol Response Mod. 1983;2(4):321–342.
   Google Scholar
• Lipton A, Harvey Ha, Lawrence B, et al. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma. Cancer. 1983;51(1):57–60.
   Web of Science ®Google Scholar
• Chirigos MA, Saito T, Talmadge JE, Budzynski W, Gruys E. Cell regulatory and immunorestorative activity of picibanil (OK432). Cancer Detect Prev Suppl. 1987;(1):317–328.
   Google Scholar
• Toso TF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142–152.
   PubMed Web of Science ®Google Scholar
• Adkins I, Holubova J, Kosova M, Sadikova L. Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol. 2012;13(8):1446–1473.
   Web of Science ®Google Scholar
• Schultz N, Oratz R, Chen D, Zeleniuch-Jacquotte A, Abeles G, Bystryn JC. Effect of DETOX as an adjuvant for melanoma vaccine. Vaccine. 1995;13(5):503–508.
   PubMed Web of Science ®Google Scholar
• Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron. 1999;30(6):597–623.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Steplewski Z, Koprowski H, et al. A new approach in specific, active immunotherapy. Cancer. 1977;39(2):560–564.
   PubMed Web of Science ®Google Scholar
• Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252(5013):1662–1667.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Madan RA, Hodge JW, Schlom J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit Rev Immunol. 2007;27(5):451–462.
   Web of Science ®Google Scholar
• Kim JW, Gulley JL. Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther. 2012;12(4):463–478.
   PubMed Web of Science ®Google Scholar
• Raquopathi G, Gardner JR, Livingston PO, Gin DY. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines. 2011;10(4):463–470.
   Web of Science ®Google Scholar
• Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anticancer vaccines: clinical results. Adv Exp Med Biol. 2010;667:111–123.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Rivoltini L, Andeola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett. 2000;74(1):41–44.
   Web of Science ®Google Scholar
• Dillman RO, Beutel LD, Barth NM, et al. Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: induction delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm. 2002;17(1):51–66.
   PubMed Web of Science ®Google Scholar
• Disis ML, Bernhard H, Shiota FM, et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide- based vaccines. Blood. 1996;88(1):202–210.
   PubMed Web of Science ®Google Scholar
• Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002; (188):147–154.
   Google Scholar
• Luiten RM, Kueter EW, Mooi W, et al. Immunogenicity, including vitiligo, and feasibility of vaccinating with autologous GM-CSF-transduced tumor cells in melanoma patients. J Clin Oncol. 2005;23(35):8978–8991.
   PubMed Web of Science ®Google Scholar
• Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce obj ective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29(5):545–557.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Reitz M. GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients. Cancer Biother Radiopharm. 2007;22(4):551–555.
   Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. JClin Oncol. 2000;18(8):1614–1621.
   PubMed Web of Science ®Google Scholar
• Spitler LE, Weber RW, Allen RE, et al. Recombinant human granulocyte- macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. JImmunother. 2009;32(6):632–637.
   Web of Science ®Google Scholar
• Dillman RO, DePriest C, de Leon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm. 2007;22(3):309–321.
   PubMed Web of Science ®Google Scholar
• Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines. 2010;9(5):519–525.
   PubMed Web of Science ®Google Scholar
• Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage- colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer. 2003;97(1):186–200.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte- macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21(21):4016–4026.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Wiemann M, Nayak SK, DeLeon C, Hood K, DePriest C. Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group. J Immunother. 2003;26(4):367–373.
   PubMed Web of Science ®Google Scholar
• Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009;15(22):7029–7035.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009;15(4):1443–1451.
   PubMed Web of Science ®Google Scholar
• Lawson DH, Lee SJ, Tarhini AA, et al. Presented at American Society of Clinical Oncology (ASCO) Annual Meeting, June 2010, Chicago, IL, USA. E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanoma. J Clin Oncol. 2010;28:15s (Suppl; abstr 8504).
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Hoon DS, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 1990;50(17):5353–5364.
   Web of Science ®Google Scholar
• Oratz R, Dugan M, Roses DF, et al. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine. Cancer Res. 1991;51(14):3643–3647.
   Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni CR, Chianese-Bullock KA, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011;29(21):2924–2932.
   PubMed Web of Science ®Google Scholar
• Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftiox DAB 389IL-2, ONTAK) to eliminate regulatory T lymphocytes inpatients with melanoma. J Immunother. 2005;28(6):582–592.
   Web of Science ®Google Scholar
• 5. Mahnke K, Schonfeld K, Fondel S, et al. Depletion of CD4+CD25+human regulatory T cell in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007;120(12):2723–2733.
   PubMed Web of Science ®Google Scholar
• Jacobs JF, Punt CJ, Lesterhuis WJ, et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010;16(20):5067–5078.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor a during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118(11):3003–3012.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828–4838.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Ileana E, Champiat S, Soria JC. Immune-checkpoints: the new anticancer immunotherapies. Bull Cancer. 2013;100(6):601–610.
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;(9):271–296.
   Google Scholar
• Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood. 1997;90(9):3245–3287.
   PubMed Web of Science ®Google Scholar
• Markiewicz MA, Kast WM. Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes. Cancer Invest. 2004;22(3):417–434.
   PubMed Web of Science ®Google Scholar
• Baggers J, Ratzinger G, Young JW. Dendritic cells as immunologic adjuvants for the treatment of cancer. J Clin Oncol. 2000;18(23):3879–3882.
   Web of Science ®Google Scholar
• de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;(9):54091–55100.
   Google Scholar
• O’Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood. 2004;104(8):2235–2246.
   PubMed Web of Science ®Google Scholar
• Fonseca C, Dranoff G. Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res. 2008;14(6):1603–1608.
   Web of Science ®Google Scholar
• Green DR, Ferguson, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9(5):353–363.
   PubMed Web of Science ®Google Scholar
• Shaif-Muthana I, McIntyre C, Sisley K, Rennie I, Murray A. Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res. 2000;60(22):6441–6447.
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Eggert AAO, Scharenborg NM, et al. Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother. 2002;25(6):429–438.
   Google Scholar
• O’Rourke MG, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007;17(5):316–322.
   Web of Science ®Google Scholar
• Verdijk P, Aarntzen EH, Lesterhuis WJ, et al. Limited amounts of dendritic cells migrate in the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15(7):2531–2540.
   PubMed Web of Science ®Google Scholar
• Rouas R, Akl H, Fayyad-Kazan H, et al. Dendritic cells generated in clinical grade bags strongly differ in immune functionality when compared with classical DC generated in plates. J Immunother. 2010;33(4):352–363.
   Web of Science ®Google Scholar
• Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4(3):328–332.
   PubMed Web of Science ®Google Scholar
• Hadzantonis M, O’Neill H. Review: dendritic cell immunotherapy for melanoma. Cancer Biother Radiopharm. 1999;14(1):11–22.
   Web of Science ®Google Scholar
• Zhang S, Wang Q, Miao B. Review: dendritic cell-based vaccine in the treatment of patients with advanced melanoma. Cancer Biother Radiopharm. 2007;22(4):501–507.
   Web of Science ®Google Scholar
• Nencioni A, Grunebach F, Schmidt SM, et al. The use of dendritic cells in cancer immunotherapy. Crit Rev Oncol Hematol. 2008;65(3):191–199.
   PubMed Web of Science ®Google Scholar
• Eubel J, Enk AH. Dendritic cell vaccination as a treatment modality for melanoma. Expert Rev Anticancer Ther. 2009;9(11):1631–1642.
   PubMed Web of Science ®Google Scholar
• Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58(1):1–14.
   PubMed Web of Science ®Google Scholar
• Herlyn M, Koprowski H. Melanoma antigens: immunological and biological characterization and clinical significance. Ann Rev Immunol. 1988;6:283–308.
   PubMed Web of Science ®Google Scholar
• Seigler HF, Wallack MK, Vervaert CE, Bash JA, Roberson KM, Stuhlmiller GM. Melanoma patient antibody responses to melanoma tumor-associated antigens defined by murine monoclonal antibodies. J Biol Response Mod. 1989;8(1):37–52.
   PubMedGoogle Scholar
• Ravindranath MH, Morton DL. Immunogenicity of membrane- bound gangliosides in viable whole-cell vaccines. Cancer Invest. 1997;15(5):491–499.
   PubMed Web of Science ®Google Scholar
• Livingston [webpage on the Internet]. Ganglioside vaccines with emphasis on GM2. Semin Oncol. 1998;25(6):636–645.
   Web of Science ®Google Scholar
• Chapman PB, Morrissey DM, Panageas KS, et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM-2keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res. 2000;6(3):874–879.
   PubMed Web of Science ®Google Scholar
• Guthmann MD, Bitton RJ, Carnero AJL, et al. Active specific immunotherapy of melanoma with a GM3 ganglioside vaccine: a report on safety and immunogenicity. J Immunother. 2004;27(6):442–451.
   Web of Science ®Google Scholar
• Foon KA, Sen G, Hutchins L, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disia- loganglioside GD2. Clin Cancer Res. 1998;4(5):1117–1124.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Morrisey D, Panageas KS, et al. Vaccination with a bivalent GM2 and GD2 ganglioside conjugate vaccine: a trial comparing doses of GD2-heyhole limpet hemocyanin. Clin Cancer Res. 2000;6(12):4658–4662.
   PubMed Web of Science ®Google Scholar
• Helling F, Shang A, Calves M, et al. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 1994;54(1):197–203.
   Web of Science ®Google Scholar
• McCaffery M, Yao TJ, Williams L, Livingston PO, Houghton AN, Chapman P. Immunization of melanoma patients with BEC2 anti- idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;2(4):679–686.
   PubMed Web of Science ®Google Scholar
• Applebaum J, Reynolds S, Knispel J, Oratz R, Shapiro R, Bystryn JC. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo. J Natl Cancer Inst. 1998;90(2):146–149.
   Google Scholar
• Kawakami Y, Dang N, Wang X, et al. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother. 2000;23(1):17–27.
   Web of Science ®Google Scholar
• Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol. 2000;182(3):323–331.
   Web of Science ®Google Scholar
• Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94(11):805–818.
   PubMed Web of Science ®Google Scholar
• Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2004;4(2):181–198.
   PubMed Web of Science ®Google Scholar
• Hodi FS. Well-defined melanoma antigens as progression markers for melanoma: insights into differential expression and host response based on stage. Clin Cancer Res. 2006;12(3 Pt 1):673–678.
   Web of Science ®Google Scholar
• Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage: 1a. Clin Cancer Res. 2006;12(3 Pt 1):764–771.
   Web of Science ®Google Scholar
• Weide B, Zelba H, Derhovanessian E, et al. Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012;30(15):1835–1841.
   PubMed Web of Science ®Google Scholar
• Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight associated antigen mimicry by mouse anti- idiotypic monoclonal antibody MK2–23: modulation of the immu- nogenicity in patients with malignant melanoma. Clin Cancer Res. 1995;1(7):705–713.
   Web of Science ®Google Scholar
• Foon KA, Lutzky J, Baral RN, et al. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol. 2000;18(2):376–384.
   PubMed Web of Science ®Google Scholar
• Osorio M, Gracia E, Reigosa E, et al. Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. Cancer Manag Res. 2012;(4): 341–345.
   Google Scholar
• Chapman PB, Wu D, Ragupathi G, et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res. 2004;10(14):4717–4723.
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12(5):1036–1044.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/ C509801. J Clin Oncol. 2001;19(9):2370–2380.
   PubMed Web of Science ®Google Scholar
• Estin CD, Stevenson US, Plowman GC, et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci U S A. 1988;85(4):1052–1056.
   Web of Science ®Google Scholar
• Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with MART-1/MelanA. Cancer J Sci Am. 1997;3(1):37–44.
   PubMed Web of Science ®Google Scholar
• Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 2003;21(12):2342–2348.
   PubMed Web of Science ®Google Scholar
• Smith JW 2nd, Walker BA, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2003;21(8):1562–1573.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175(9):6169–6176.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Carrillo C, Urba WJ, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008;26(14):2292–2298.
   Web of Science ®Google Scholar
• Lesterhuis WJ, Schreibelt G, Scharenborg NM, et al. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother. 2011;60(2):249–260.
   PubMed Web of Science ®Google Scholar
• Marchand M, Punt CJ, Aamdal S, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. 2003;39(1):70–77.
   PubMed Web of Science ®Google Scholar
• Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer. 2005;117(4):596–604.
   PubMed Web of Science ®Google Scholar
• van Baren N, Bonnet MC, Dreno B, et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE regions recognized by T cells. J Clin Oncol. 2005;23(35):9008–9021.
   Web of Science ®Google Scholar
• Hersey P, Menzies SW, Halliday GM, et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol Immunother. 2004;53(2):125–134.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Cheung E, Banta W, Gee C, Weber JS. Survival analysis after resection of metastatic disease followed by peptide vaccines in patients with stage IV melanoma. Cancer. 2006;106(6):1353–1357.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Leng S, Moschos SJ, et al. Safety and immunogenicity of vaccination with MART-1 (26–35, 27 L), gp100 (209–217, 210M), and tyrosinase (368–376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012;35(4):359–366.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide- pulsed dendritic cells derived from CD34+ progenitors and activated with type 1 interferon. J Immunother. 2005;28(5):505–516.
   PubMed Web of Science ®Google Scholar
• Hersey P, Halliday GM, Farrelly ML, et al. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol Immunother. 2008;57(7):1039–1051.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26(30):4973–4980.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22(22):4474–4485.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, et al; DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17(4):563–570.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni BR, Chianese-Bullock KA, et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res. 2007;13(21):6386–6395.
   PubMed Web of Science ®Google Scholar
• Kruit WH, Suciu S, Dreno B, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized Phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in metastatic melanoma. J Clin Oncol. 2013;(19):2413–2420.
   Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–2127.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Matsuzaki J, Karbach J, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA. 2012;109(15):5797–5802.
   PubMed Web of Science ®Google Scholar
• McGee JM, Lytle GH, Malnar KF, Price JA, Humphrey LJ. Melanoma tumor vaccine: five-year follow-up. J Surg Oncol. 1991 ;47(4): 233–238.
   Google Scholar
• McGee JM, Patten MR, Malnar KF, Price JA 3rd, Mayes JS, Watson GH. Comparison of melanoma antigens in whole tumor vaccine to those from IIB-MEL-J Cells. Cancer Biother Radiopharm. 1999;14(3):203–208.
   Web of Science ®Google Scholar
• Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma tumor-associated antigens (TAA) in specific-active immunochemo- therapy of malignant melanoma. Cancer. 1982;49(7):1387–1404.
   Web of Science ®Google Scholar
• Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001;7(7):1882–1887.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, et al. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer. 1995;75(1):34–42.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Sivanandham M, Balch CM, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg. 1998;187(1):69–77.
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002;20(20):4181–4190.
   PubMed Web of Science ®Google Scholar
• Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20(8):2058–2066.
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol. 2007;25(15):2078–2085.
   Web of Science ®Google Scholar
• Morton DL, Mozzillo N, Thompson JF, et al. Presented at American Society of Clinical Oncology (ASCO) Annual Meeting, June 2007, Chicago, IL, USA. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. 2007;25:474s (abstr 8508).
   Google Scholar
• Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216(4):463–482.
   PubMed Web of Science ®Google Scholar
• Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20(23):4549–4554.
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Oratx R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer. 1988;61(6):1065–1070.
   Web of Science ®Google Scholar
• Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55(7):819–829.
   PubMed Web of Science ®Google Scholar
• Lopez MN, Pereda C, Segal G, et al. Prolonged survival of dendritic cell- vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing cells. J Clin Oncol. 2009;27(6):945–952.
   PubMed Web of Science ®Google Scholar
• Ribas A, Camacho LH, Lee SM, et al. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. JTransl Med. 2010;8:89.
   Web of Science ®Google Scholar
• Laucius JF, Bodurtha AJ, Mastrangelo MJ, Bellet RE. A phase II sutdy of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 1977;40(5):2091–2093.
   Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990;8(11):1858–1867.
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, Schuchter LM, et al. Autologous hapten- modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol. 1997;15(6):2359–2370.
   PubMed Web of Science ®Google Scholar
• Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous hapten-modified human melanoma vaccine. J Clin Oncol. 2004;22(3):403–415.
   PubMed Web of Science ®Google Scholar
• Eton O, Kharkevitch DD, Gianan MA, et al. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res. 1998;4(3):619–627.
   PubMed Web of Science ®Google Scholar
• O’Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/ dendritic cell vaccine. Cancer Immunol Immunother. 2003;52(6):387–395.
   PubMed Web of Science ®Google Scholar
• Ridolfi L, Petrini M, Fiammenghi L, et al. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome. Melanoma Res. 2011;21(6):524–529.
   PubMed Web of Science ®Google Scholar
• Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother. 2008;31(6):591–598.
   PubMed Web of Science ®Google Scholar
• Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andressen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother. 2002;25(5):421–428.
   PubMed Web of Science ®Google Scholar
• Haenssle H, Krause SW, Emmert S, et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a phase I/II study. J Immunother. 2004;27(2):147–155.
   PubMed Web of Science ®Google Scholar
• Wei Y, Sticca RP, Holmes LM, et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol. 2006;28(3):585–593.
   PubMed Web of Science ®Google Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines. 2004;3(5):521–527.
   PubMedGoogle Scholar
• Berd D. A tale of two pities: autologous melanoma vaccines on the brink. Hum Vaccin Immunother 2012;8(8):1146–1151.
   PubMed Web of Science ®Google Scholar
• Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y. A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dendritomas. J Immunother. 2001;24(2):122–129.
   PubMed Web of Science ®Google Scholar
• Soruri A, Fayyazi, Neumann C, et al. Ex vivo generation of human anti-melanoma autologous cytolytic T cells by dendritic cell/ melanoma cell hybridomas. Cancer Immunol Immunother. 2001;50(6):307–3014.
   Web of Science ®Google Scholar
• Srivastava PK, Jaikaria NS. Methods of purification of heat shock protein-peptide complexes for use as vaccines against cancers and infectious diseases. Methods Mol Biol. 2001;(156):175–186.
   Google Scholar
• Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20(20):4169–4180.
   PubMed Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E, et al; C-100–21 Study Group. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100–21 Study Group. J Clin Oncol. 2008;26(6):955–962.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother. 1993;14(1):65–69.
   Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Nistor G. Cancer stem cell antigen- based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma? Expert Opin Biol Ther. 2013;13(5):643–656.
   PubMed Web of Science ®Google Scholar
• Schatton T, Frank MH. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008;21(1):39–55.
   PubMed Web of Science ®Google Scholar
• Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci. 2009;1176:154–169.
   PubMed Web of Science ®Google Scholar
• Boiko AD, Razorenova OV, van de, Rijn M, et al. Human melanoma- initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010;466(7302):133–137.
   PubMed Web of Science ®Google Scholar
• Civennia G, Kobert N, Mihic-Probst D, et al. Human CD271- positive melanoma stems cell associated with metastasis establish tumor heterogeneity and long-term growth. Cancer Res. 2011;71(8):3098–3109.
   Web of Science ®Google Scholar
• Ramgolam K, Lauriol J, Lalou C, et al. Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS One. 2011;6(4):e18784.
   Web of Science ®Google Scholar
• Lang D, Mascarenhas JB, Shea CR. Melanocytes, melancyte stem cells, and melanoma stem cells. Clin Dermatol. 2013;31(2):166–178.
   Web of Science ®Google Scholar
• Boiko AD. Isolation of melanoma tumor-initiating cells from surgical tissues. Methods Mol Biol. 2013;961:253–259.
   PubMedGoogle Scholar
• Schmidt P Kopecky C, Hombach A, Zigrino P, Mauch C, Abken H. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U SA. 2011;8:108(6):2474–2479.
   Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schlitz PM. Patient-specific dendritic cell vaccines for metastatic melanoma. N Engl J Med. 2006;355(11):1179–1181.
   PubMed Web of Science ®Google Scholar
• Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 2010;20(4):280–292.
   PubMed Web of Science ®Google Scholar
• Cornforth AN, Fowler AW, Carbonell DJ, Fan E, Dillman RO. Characterization of interferon-y-treated melanoma tumor cells for use in dendritic cell-based immunotherapy. Cancer Biother Radiopharm. 2011;26(3):345–351.
   Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009;24(3):311–319.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Depriest C, et al. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35(8):641–649.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Nanci AA, Williams ST, et al. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm. 2010;25(5):553–557.
   Web of Science ®Google Scholar
• Cornforth AN, Fowler AW, Carbonell DJ, Dillman RO. Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival. Cancer Immunol Immunother. 2011;60(1):123–131.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific vaccines consisting of proliferating autologous tumor cells and autologous dendritic cells. Cancer Biother Radiopharm. 2011;26(4):407–415.
   Web of Science ®Google Scholar
• Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I trial of immunotherapy with interferon-Y gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer. 1997;80(3):401–412.
   Web of Science ®Google Scholar
• Kusumoto M, Umeda S, Ikubo A, et al. Phase I clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol Immunother. 2001;50(7):373–381.
   PubMed Web of Science ®Google Scholar
• Soiffer R, Hodi S, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte- macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21(17):3343–3350.
   PubMed Web of Science ®Google Scholar
• Triozzi PL, Tuthill RJ, Borden E. Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy. 2011;3(5):653–671.
   PubMed Web of Science ®Google Scholar
• Tan JK, Ho VC. Pooled analysis of the efficacy of bacilli Calmette- Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol. 1993;19(11):985–990.
   Google Scholar
• Von Wussow P, Block B, Hartmann F, Deicher H. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988;61(6):1071–1074.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Fong T, Burrows F, et al. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther. 1999;10(8):1289–1298.
   Web of Science ®Google Scholar
• Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. Cancer. 2010;116(17):4139–4146.
   PubMed Web of Science ®Google Scholar
• Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res. 1996;6(3):247–255.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET, et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 1997;15(1):341–349.
   Web of Science ®Google Scholar
• Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/ß2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 2001;7(8):2285–2291.
   Web of Science ®Google Scholar
• Bedikian AY, Richards J, Kharkevitch D, Atkins MB, Whitman E, Gonzalez R. A phase 2 study of high-dose allovectin-7 in patients with advanced metastatic melanoma. Melanoma Res. 2010;20(3):218–226.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncyloytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34):5763–5771.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF inpatients with stage IIIC and IV melanoma. Ann Surg Oncol. 2010;17(3):718–730.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Lutzky J, Clark J, et al. OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol. 2013;31 (Suppl; abstr LBA9008).
   Google Scholar
• Edge SB, Byrd DR, Compton CC, Fritz AG, Green FL, Trotti A, editors. Melanoma of the skin. In: Cancer Staging Manual. 7th ed. American Joint Committee on Cancer (AJCC); Springer, NY, USA 2010:387–415.
   Google Scholar